Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: could your body clock influence lung cancer?

NCT ID NCT05988970

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether the time of day affects the number of cancer cells in the blood of people with advanced lung cancer. Researchers took blood samples from 27 patients at 4 a.m. and 10 a.m. before starting treatment. The goal was to see if circadian rhythms influence how cancer spreads, which could one day help time treatments for better effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors understand the best time of day to treat lung cancer to reduce the risk of cancer spreading.
What could go wrong
This is a very small pilot study with only 27 participants, so results may not apply to all lung cancer patients. It is designed to gather information, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Jan 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with histologically confirmed advanced NSCLC (inoperable stage 3 or 4) 2. Patient aged ≥ 18 years 3. Life expectancy \> 3 months 4. Patient naïve to treatment for NSCLC 5. Patient hospitalized at least one night for initiation of specific treatment (chemotherapy, radiotherapy, surgery, other...) 6. Patient with no other active cancer. Cancer history accepted if more than 3 years old and considered cured. 7. Patient affiliated to a Social Security scheme in France. 8. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: 1. Small-cell cancer or cancer with a majority small-cell contingent 2. Patient previously treated for NSCLC 3. Outpatient 4. Patient with active pathology such as sepsis or uncontrolled inflammatory syndrome 5. Any pathology contraindicating the sample collection procedures required by the study. 6. Pregnant or breast-feeding women. 7. Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical follow-up and/or procedures stipulated in the study protocol. 8. Patients deprived of their liberty or under legal protection (guardianship, legal protection).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm Neoplastic Cells, Circulating non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • Hôpital Larrey

    Toulouse, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.